Scleroderma is a disorder that can take various forms: localized scleroderma (morphea), limited scleroderma (such as CREST syndome), and systemic sclerosis.
Dr. Sherber authored the skin chapter in the definitive textbook on scleroderma, now in second edition, and has cared for many patients with scleroderma.
In the various forms of scleroderma, tissues harden due to autoimmune activity targeting them.
Early signs can be subtle, and the cutting edge of treatment hinges on early diagnosis.
Dr. Sherber works closely with rheumatologists and other specialists to ensure comprehensive care of her scleroderma patients, and often suggests that new patients with active disease have an evaluation at The Johns Hopkins Scleroderma Center with her colleague Dr. Fredrick Wigley.
Our staff can assist you in coordinating additional consultations, and will ensure that your records are shared with your medical team to give you seamless multidisciplinary care.
Active inflammatory stages of scleroderma must be treated thoroughly, and Dr. Sherber prescribes various topical or systemic approaches as needed, with every effort made to limit the use of steroids in order to prevent their long term effects.
Mat telangiectasias can be treated safely and effectively with the Nd:YAG laser.
Pronounced skin wrinkling and facial volume loss that can occur once disease becomes inactive can be treated with injectable dermal fillers such as Voluma.
Mineral sun protection, either with mineral-only formulations of sunscreen or with those that combine mineral and chemical sun filters, is emphasized in those with scleroderma because it will best prevent hyperpigmentation in areas of active inflammation.